Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin(Trinity College Dublin), Jeffrey S. Weber(NYU Langone Health), Marcus O. Butler(University of Toronto), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Luis de la Cruz‐Merino, Leslie A. Fecher(University of Pennsylvania), Anna Maria Di Giacomo(University of Siena), Michael Schenker(Sorbonne Université), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Petr Arenberger(Charles University), Charles Lance Cowey(Baylor University), Jose Lutzky, Andrew G. Hill(Trans Tasman Radiation Oncology Group), Mark R. Middleton(University of Oxford), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Maurice Lobo(Bristol-Myers Squibb (United States)), Jean‐Jacques Grob(Aix-Marseille Université), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), Margarita Askelson(Bristol-Myers Squibb (United States)), Hao Tang(Bristol-Myers Squibb (United States)), Michael Millward(The University of Western Australia), Victoria Atkinson(The University of Queensland), Corey Ritchings(Bristol-Myers Squibb (United States)), Paul Nathan(Mount Vernon Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Helen Gogas(National and Kapodistrian University of Athens), Sonia Dolfi(Bristol-Myers Squibb (United States))
Cited by 185
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k